fluoxetine has been researched along with Weight Reduction in 60 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This open-label pilot study of combination therapy of metformin and fluoxetine gave encouraging weight reduction, and these results suggest the need for a randomized double-blind clinical trial comparing the two components and the combination to placebo." | 9.12 | An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. ( Amini, M; Aminorroaya, A; Dastjerdi, MS; Kazemi, F; Mohammady, M; Najafian, A, 2007) |
| "To evaluate the weight reducing effect of fluoxetine on steroid-induced obesity, we conducted an open, clinical intervention study of 20-40 mg/day fluoxetine, 24 weeks duration." | 9.09 | Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. ( Achiron, A; Barak, Y; Noy, S; Pinhas-Hamiel, O, 1999) |
| "This study compared nortriptyline and fluoxetine with placebo in the treatment of depression and in recovery from physical and cognitive impairments after stroke." | 9.09 | Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. ( Castillo, C; Curdue, K; Kopel, T; Kosier, JT; Newman, RM; Petracca, G; Robinson, RG; Schultz, SK; Starkstein, SE, 2000) |
| "To study the effect of fluoxetine, a specific serotonin reuptake inhibitor, on insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus (NIDDM) independently of its action on body weight." | 9.08 | Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. ( Bourque, J; Chiasson, JL; Ducros, F; Garon, J; Maheux, P, 1997) |
| "Our study aims at assessing the efficacy and safety of fluoxetine as compared with placebo in the treatment of obesity using a double-blind crossover design." | 9.08 | Comparison of fluoxetine and placebo in the treatment of obesity. ( Barredo-Acedo, F; Escobar-Jiménez, F; Fernández-Soto, ML; González-Jiménez, A; Luna del Castillo, JD, 1995) |
| "Fluoxetine hydrochloride (Lovan, Eli Lilly and Company, Indianapolis, Indiana, USA), a specific serotonin uptake inhibitor, was compared with placebo in 458 obese outpatients in a 52-week double-blind randomized ten-site trial to study its effect on weight reduction." | 9.07 | Fluoxetine: a randomized clinical trial in the treatment of obesity. ( Enas, GG; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1994) |
| " To demonstrate the use of this methodology, we applied the criteria in an analysis of eight randomized, double-blind controlled trials comparing fluoxetine (n = 522) with placebo (n = 504) for weight loss." | 9.07 | Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data. ( Atkinson, RL; Goldstein, DJ; Roback, PJ; Sayler, ME, 1994) |
| " Fluoxetine, an inhibitor of serotonin reuptake, decreases food intake in animals and is associated with weight loss in depressed and otherwise healthy obese patients." | 9.06 | Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub). ( Byyny, RL; Dauer, AD; Enas, GG; Kirby, RW; Kreindler, TG; Levine, LR; Levy, B; Lucas, CP; McIlwain, HH; Thompson, WL, 1989) |
| "Eleven healthy male subjects of normal body weight received either 60 mg of the 5-HT re-uptake inhibitor fluoxetine (FXT) or matching placebo daily for two weeks, with a minimum one month wash-out period between treatments." | 9.06 | The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. ( McGuirk, J; Silverstone, T, 1990) |
| "The rising popularity of herbal medicine as a weight loss remedy, fueled by misleading propaganda, raises concerns about the manufacturing processes and potential inclusion of controlled substances such as fluoxetine (FLU)." | 8.31 | Determination of Fluoxetine in Weight Loss Herbal Medicine Using an Electrochemical Sensor Based on rGO-CuNPs. ( Barreto, FC; Cesarino, I; Melaré, AG; Silva, MKL; Simões, RP, 2023) |
| "Fluoxetine is a highly specific serotonin reuptake inhibitor." | 7.77 | Clinical studies with fluoxetine in obesity. ( Wise, SD, 1992) |
| "These data suggest that fluoxetine and olanzapine treatment decreases weight gain in rats; a pharmacodynamic event-related effect that differs considerably from what is observed in the clinical condition." | 7.72 | Weight loss dynamics during combined fluoxetine and olanzapine treatment. ( Chabla, JM; Hallas, BH; Horowitz, JM; Perrone, JA; Torres, G, 2004) |
| "Fluoxetine, a serotonin re-uptake inhibitor with antidepressive and appetite reduction effects, could improve insulin sensitivity." | 7.69 | [The effect of fluoxetine on insulin resistance in non diabetic obese patients]. ( Aguirre, C; Araya, V; Contreras, P; Depix, MS; Zura, ML, 1995) |
| "A 27-year-old woman experienced a modest weight loss during treatment for depression with fluoxetine." | 7.69 | Hyperphagia and weight loss during fluoxetine treatment. ( Braun, BG; Fichtner, CG, 1994) |
| " To examine whether weight loss produced by serotoninergic drugs involves a selective reduction in CHO intake, obese females who consumed at least 30% of their daily calories from CHO-rich snacks were treated with dexfenfluramine ([DF] 15 mg b." | 7.68 | Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. ( Berry, E; Gleason, R; Goldberg, H; Kahne, M; McDermott, J; Tsay, R; Wurtman, J; Wurtman, R, 1993) |
| "Fluoxetine treatment was associated with greater reduction in depressive symptoms (p<0." | 6.71 | Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. ( Bellace, D; Carino, J; Devlin, MJ; Dobrow, I; Goldfein, JA; Jiang, H; Kamenetz, C; Mayer, L; Petkova, E; Raizman, PS; Walsh, BT; Wolk, S, 2005) |
| "Obesity is a major health care concern because of its associated medical complications and increased mortality." | 6.68 | Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success. ( Goldstein, DJ; Hamilton, SH; Rampey, AH; Roback, PJ; Sayler, ME; Tollefson, GD; Wilson, MG, 1995) |
| "Fluoxetine 60 mg/day was effective for a longer period than fluoxetine 20 mg/day or placebo in maintaining weight loss." | 6.67 | Fluoxetine: a randomized clinical trial in the maintenance of weight loss. ( Dornseif, BE; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1993) |
| "To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss." | 5.19 | A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. ( Boguszewski, CL; Cunha, DR; do Desterro de Figueiredo, M; dos Santos, CM; Radominski, R; Suplicy, H, 2014) |
| "This open-label pilot study of combination therapy of metformin and fluoxetine gave encouraging weight reduction, and these results suggest the need for a randomized double-blind clinical trial comparing the two components and the combination to placebo." | 5.12 | An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. ( Amini, M; Aminorroaya, A; Dastjerdi, MS; Kazemi, F; Mohammady, M; Najafian, A, 2007) |
| "This study compared nortriptyline and fluoxetine with placebo in the treatment of depression and in recovery from physical and cognitive impairments after stroke." | 5.09 | Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. ( Castillo, C; Curdue, K; Kopel, T; Kosier, JT; Newman, RM; Petracca, G; Robinson, RG; Schultz, SK; Starkstein, SE, 2000) |
| "To evaluate the weight reducing effect of fluoxetine on steroid-induced obesity, we conducted an open, clinical intervention study of 20-40 mg/day fluoxetine, 24 weeks duration." | 5.09 | Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. ( Achiron, A; Barak, Y; Noy, S; Pinhas-Hamiel, O, 1999) |
| "Fluoxetine has been associated with weight loss during acute treatment, but no controlled studies of weight change during long-term treatment with fluoxetine or other selective serotonin reuptake inhibitors have been reported." | 5.09 | Changes in weight during a 1-year trial of fluoxetine. ( Amsterdam, JD; Beasley, CM; Kim, Y; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Zajecka, J, 1999) |
| "This study assessed the effect of fluoxetine 20 mg/day on weight loss in older patients treated for major depression in a multicenter, double-blind placebo-controlled, 6-week clinical trial." | 5.08 | Fluoxetine in medically stable, depressed geriatric patients: effects on weight. ( Beasley, CM; Goldstein, DJ; Hamilton, SH; Masica, DN, 1997) |
| "To study the effect of fluoxetine, a specific serotonin reuptake inhibitor, on insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus (NIDDM) independently of its action on body weight." | 5.08 | Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. ( Bourque, J; Chiasson, JL; Ducros, F; Garon, J; Maheux, P, 1997) |
| " We have evaluated the weight loss of a selective inhibitor of serotonin uptake, fluoxetine, alone as compared with combined therapeutic trial with another serotoninergic drug, dexfenfluramine." | 5.08 | The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. ( Halpern, A; Lima, N; Medeiros-Neto, G; Pedrinola, F; Sztejnsznajd, C, 1996) |
| "Our study aims at assessing the efficacy and safety of fluoxetine as compared with placebo in the treatment of obesity using a double-blind crossover design." | 5.08 | Comparison of fluoxetine and placebo in the treatment of obesity. ( Barredo-Acedo, F; Escobar-Jiménez, F; Fernández-Soto, ML; González-Jiménez, A; Luna del Castillo, JD, 1995) |
| "Fluoxetine hydrochloride (Lovan, Eli Lilly and Company, Indianapolis, Indiana, USA), a specific serotonin uptake inhibitor, was compared with placebo in 458 obese outpatients in a 52-week double-blind randomized ten-site trial to study its effect on weight reduction." | 5.07 | Fluoxetine: a randomized clinical trial in the treatment of obesity. ( Enas, GG; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1994) |
| "Fluoxetine, an inhibitor of serotonin re-uptake, has been shown to cause weight loss in humans and animals." | 5.07 | Fluoxetine treatment of the obese diabetic. ( Bray, GA; Devine, W; Fujioka, K; Gray, DS, 1992) |
| " To demonstrate the use of this methodology, we applied the criteria in an analysis of eight randomized, double-blind controlled trials comparing fluoxetine (n = 522) with placebo (n = 504) for weight loss." | 5.07 | Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data. ( Atkinson, RL; Goldstein, DJ; Roback, PJ; Sayler, ME, 1994) |
| "To determine whether fluoxetine is effective in the long-term treatment of obesity and whether it is particularly useful in the treatment of obese binge-eaters, the authors randomly assigned 45 obese subjects (22 with binge-eating problems and 23 without binge-eating) to fluoxetine (60 mg/day) or placebo in a 52-week double-blind trial." | 5.06 | A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. ( Ewing, L; Gooding, W; Kern, E; Marcus, MD; McDermott, M; Wing, RR, 1990) |
| " Fluoxetine, an inhibitor of serotonin reuptake, decreases food intake in animals and is associated with weight loss in depressed and otherwise healthy obese patients." | 5.06 | Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub). ( Byyny, RL; Dauer, AD; Enas, GG; Kirby, RW; Kreindler, TG; Levine, LR; Levy, B; Lucas, CP; McIlwain, HH; Thompson, WL, 1989) |
| "Eleven healthy male subjects of normal body weight received either 60 mg of the 5-HT re-uptake inhibitor fluoxetine (FXT) or matching placebo daily for two weeks, with a minimum one month wash-out period between treatments." | 5.06 | The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. ( McGuirk, J; Silverstone, T, 1990) |
| "Short period of fluoxetine therapy can lead to weight loss as well as reduction of FPG, HbA1c and TG in T2DM." | 4.87 | Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. ( Chen, L; He, M; Hu, J; Hu, R; Huang, Y; Li, Q; Liu, C; Qu, S; Wang, X; Yang, Z; Ye, Z; Zhang, S; Zhang, Z; Zhao, W, 2011) |
| "Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 26 to 52 weeks." | 4.82 | Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. ( Avenell, A; Gregg, E; Kim, C; Lau, J; Norris, SL; Schmid, CH; Zhang, X, 2004) |
| "Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 12 to 57 weeks." | 4.82 | Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. ( Avenell, A; Gregg, E; Lau, J; Norris, SL; Schmid, CH; Zhang, X, 2005) |
| "The rising popularity of herbal medicine as a weight loss remedy, fueled by misleading propaganda, raises concerns about the manufacturing processes and potential inclusion of controlled substances such as fluoxetine (FLU)." | 4.31 | Determination of Fluoxetine in Weight Loss Herbal Medicine Using an Electrochemical Sensor Based on rGO-CuNPs. ( Barreto, FC; Cesarino, I; Melaré, AG; Silva, MKL; Simões, RP, 2023) |
| "Fluoxetine is a highly specific serotonin reuptake inhibitor." | 3.77 | Clinical studies with fluoxetine in obesity. ( Wise, SD, 1992) |
| "Bupropion (BUP) is a dopamine (DA) and norepinephrine (NE) reuptake inhibitor that causes mild weight loss in obese adults." | 3.74 | Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. ( Billes, SK; Cowley, MA, 2008) |
| "These data suggest that fluoxetine and olanzapine treatment decreases weight gain in rats; a pharmacodynamic event-related effect that differs considerably from what is observed in the clinical condition." | 3.72 | Weight loss dynamics during combined fluoxetine and olanzapine treatment. ( Chabla, JM; Hallas, BH; Horowitz, JM; Perrone, JA; Torres, G, 2004) |
| " To illustrate an application of this method, we used data from 1,026 patients completing at least 6 months of double-blind therapy in clinical trials comparing fluoxetine (N=522) with placebo (N=504) for weight loss." | 3.69 | Baseline predictors of success when comparing two treatments. ( Goldstein, DJ; Rampey, AH; Roback, PJ; Wilson, MG, 1994) |
| "Fluoxetine, a serotonin re-uptake inhibitor with antidepressive and appetite reduction effects, could improve insulin sensitivity." | 3.69 | [The effect of fluoxetine on insulin resistance in non diabetic obese patients]. ( Aguirre, C; Araya, V; Contreras, P; Depix, MS; Zura, ML, 1995) |
| " To investigate this phenomenon as a possible animal model of obsessive-compulsive disorder (OCD), rats were treated for 5 weeks with fluoxetine, an antidepressant that relieves OCD symptoms in humans (5 mg/kg, 2." | 3.69 | Effects of serotonergic agents on food-restriction-induced hyperactivity. ( Altemus, M; Galliven, E; Glowa, JR; Leong, YM; Murphy, DL, 1996) |
| "A 27-year-old woman experienced a modest weight loss during treatment for depression with fluoxetine." | 3.69 | Hyperphagia and weight loss during fluoxetine treatment. ( Braun, BG; Fichtner, CG, 1994) |
| "The frequency and degree of weight loss noted here in medically ill elderly receiving fluoxetine warrants further investigation." | 3.68 | Fluoxetine in elderly patients: is there cause for concern? ( Brymer, C; Winograd, CH, 1992) |
| " To examine whether weight loss produced by serotoninergic drugs involves a selective reduction in CHO intake, obese females who consumed at least 30% of their daily calories from CHO-rich snacks were treated with dexfenfluramine ([DF] 15 mg b." | 3.68 | Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers. ( Berry, E; Gleason, R; Goldberg, H; Kahne, M; McDermott, J; Tsay, R; Wurtman, J; Wurtman, R, 1993) |
| "Fluoxetine treatment was associated with greater reduction in depressive symptoms (p<0." | 2.71 | Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. ( Bellace, D; Carino, J; Devlin, MJ; Dobrow, I; Goldfein, JA; Jiang, H; Kamenetz, C; Mayer, L; Petkova, E; Raizman, PS; Walsh, BT; Wolk, S, 2005) |
| " FL did not affect thermic response to oral glucose neither after acute nor chronic administration (p=NS for all groups studied)." | 2.69 | Metabolic effects of fluoxetine in obese menopausal women. ( Bertolini, M; Bondi, M; Del Rio, G; Menozzi, R; Venneri, MG, 2000) |
| "Weight reduction is essential in the management of most non-insulin-dependent diabetics, but this therapeutical goal is difficult to obtain." | 2.68 | Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. ( Daubresse, JC; Kolanowski, J; Krzentowski, G; Kutnowski, M; Scheen, A; Van Gaal, L, 1996) |
| "Obesity is a major health care concern because of its associated medical complications and increased mortality." | 2.68 | Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success. ( Goldstein, DJ; Hamilton, SH; Rampey, AH; Roback, PJ; Sayler, ME; Tollefson, GD; Wilson, MG, 1995) |
| "Fluoxetine 60 mg/day was effective for a longer period than fluoxetine 20 mg/day or placebo in maintaining weight loss." | 2.67 | Fluoxetine: a randomized clinical trial in the maintenance of weight loss. ( Dornseif, BE; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1993) |
| "After treatment, weight loss (on average) was observed in both groups: -2." | 2.67 | The effect of fluoxetine on body weight, body composition and visceral fat accumulation. ( Koppeschaar, HP; Seidell, JC; Smits, P; Visser, M, 1993) |
| "Fluoxetine is an antidepressant drug with weight reducing properties." | 2.67 | An assessment of the thermogenic effects of fluoxetine in obese subjects. ( Andrews, JF; Murphy, CM; Stinson, JC; Tomkin, GH, 1992) |
| "Weight loss was significantly higher in the fluoxetine-treated patients, whose diabetic status improved." | 2.67 | Fluoxetine therapy in obese diabetic and glucose intolerant patients. ( Daubresse, JC; Friedman, H; Kolanowski, J; Krzentowski, G; Kutnowski, M; Scheen, A; Van Gaal, L, 1992) |
| "Fluoxetine and trazodone were compared in a double-blind, randomized, parallel, 6-week trial in 43 outpatients with major depression after a 1-week single-blind placebo period." | 2.66 | Fluoxetine versus trazodone in the treatment of outpatients with major depression. ( Debus, JR; Himmel, C; Polatin, P; Rush, AJ; Tyler, D; Weissenburger, J, 1988) |
| "The resultant weight loss is variable and there appears to be no way of predicting good responders, nor is there evidence that additional weight loss attributable to drug therapy is sustained once treatment is discontinued, although nonpharmacological strategies for preventing weight regain are worthy of exploration." | 2.38 | Appraisal of the clinical value of serotoninergic drugs. ( Hodge, J; Munro, JF; Scott, C, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.00) | 18.7374 |
| 1990's | 37 (61.67) | 18.2507 |
| 2000's | 16 (26.67) | 29.6817 |
| 2010's | 2 (3.33) | 24.3611 |
| 2020's | 2 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Melaré, AG | 1 |
| Barreto, FC | 1 |
| Silva, MKL | 1 |
| Simões, RP | 1 |
| Cesarino, I | 1 |
| de Souza, JA | 1 |
| do Amaral Almeida, LC | 1 |
| Tavares, GA | 1 |
| Falcão, LAL | 1 |
| Beltrão, LC | 1 |
| Costa, FCO | 1 |
| de Souza, FL | 1 |
| da Silva, MC | 1 |
| de Souza, SL | 1 |
| Suplicy, H | 1 |
| Boguszewski, CL | 1 |
| dos Santos, CM | 1 |
| do Desterro de Figueiredo, M | 1 |
| Cunha, DR | 1 |
| Radominski, R | 1 |
| Yanover, T | 1 |
| Thompson, JK | 1 |
| Straub, DM | 1 |
| Kaplan, AS | 1 |
| Walsh, BT | 2 |
| Olmsted, M | 1 |
| Attia, E | 1 |
| Carter, JC | 1 |
| Devlin, MJ | 2 |
| Pike, KM | 1 |
| Woodside, B | 1 |
| Rockert, W | 1 |
| Roberto, CA | 1 |
| Parides, M | 1 |
| Ye, Z | 1 |
| Chen, L | 1 |
| Yang, Z | 1 |
| Li, Q | 1 |
| Huang, Y | 1 |
| He, M | 1 |
| Zhang, S | 1 |
| Zhang, Z | 1 |
| Wang, X | 1 |
| Zhao, W | 1 |
| Hu, J | 1 |
| Liu, C | 1 |
| Qu, S | 1 |
| Hu, R | 1 |
| Norris, SL | 2 |
| Zhang, X | 2 |
| Avenell, A | 2 |
| Gregg, E | 2 |
| Schmid, CH | 2 |
| Kim, C | 1 |
| Lau, J | 2 |
| Weng, CS | 1 |
| Hung, YL | 1 |
| Shyu, LY | 1 |
| Chang, YH | 1 |
| Perrone, JA | 1 |
| Chabla, JM | 1 |
| Hallas, BH | 1 |
| Horowitz, JM | 1 |
| Torres, G | 1 |
| Goldfein, JA | 1 |
| Petkova, E | 1 |
| Jiang, H | 1 |
| Raizman, PS | 1 |
| Wolk, S | 1 |
| Mayer, L | 1 |
| Carino, J | 1 |
| Bellace, D | 1 |
| Kamenetz, C | 1 |
| Dobrow, I | 1 |
| Dolfing, JG | 1 |
| Wolffenbuttel, BH | 1 |
| ten Hoor-Aukema, NM | 1 |
| Schweitzer, DH | 1 |
| Goldstein, DJ | 7 |
| Rampey, AH | 4 |
| Dornseif, BE | 1 |
| Levine, LR | 3 |
| Potvin, JH | 2 |
| Fludzinski, LA | 2 |
| Roback, PJ | 3 |
| Wilson, MG | 2 |
| Dastjerdi, MS | 1 |
| Kazemi, F | 1 |
| Najafian, A | 1 |
| Mohammady, M | 1 |
| Aminorroaya, A | 1 |
| Amini, M | 1 |
| Whigham, LD | 1 |
| Dhurandhar, NV | 1 |
| Rahko, PS | 1 |
| Atkinson, RL | 2 |
| Billes, SK | 1 |
| Cowley, MA | 1 |
| Toubro, S | 1 |
| Fernández-Soto, ML | 1 |
| González-Jiménez, A | 1 |
| Barredo-Acedo, F | 1 |
| Luna del Castillo, JD | 1 |
| Escobar-Jiménez, F | 1 |
| Barak, Y | 2 |
| Lampl, Y | 1 |
| Achiron, A | 2 |
| Sarova-Pinhas, I | 1 |
| Elizur, A | 1 |
| Connolly, VM | 1 |
| Gallagher, A | 1 |
| Kesson, CM | 1 |
| Fichtner, CG | 1 |
| Braun, BG | 1 |
| Gray, DS | 2 |
| Bross, R | 1 |
| Hoffer, LJ | 1 |
| Sayler, ME | 2 |
| Holman, SL | 1 |
| Enas, GG | 3 |
| Porterfield, LM | 1 |
| Wurtman, J | 1 |
| Wurtman, R | 1 |
| Berry, E | 1 |
| Gleason, R | 1 |
| Goldberg, H | 1 |
| McDermott, J | 1 |
| Kahne, M | 1 |
| Tsay, R | 1 |
| Visser, M | 1 |
| Seidell, JC | 1 |
| Koppeschaar, HP | 1 |
| Smits, P | 1 |
| Araya, V | 1 |
| Contreras, P | 1 |
| Aguirre, C | 1 |
| Depix, MS | 1 |
| Zura, ML | 1 |
| Hamilton, SH | 2 |
| Tollefson, GD | 1 |
| Daubresse, JC | 2 |
| Kolanowski, J | 2 |
| Krzentowski, G | 2 |
| Kutnowski, M | 2 |
| Scheen, A | 2 |
| Van Gaal, L | 2 |
| Altemus, M | 1 |
| Glowa, JR | 1 |
| Galliven, E | 1 |
| Leong, YM | 1 |
| Murphy, DL | 1 |
| Foltin, RW | 1 |
| Haney, M | 1 |
| Comer, SD | 1 |
| Fischman, MW | 1 |
| Pedrinola, F | 1 |
| Sztejnsznajd, C | 1 |
| Lima, N | 1 |
| Halpern, A | 1 |
| Medeiros-Neto, G | 1 |
| Maheux, P | 1 |
| Ducros, F | 1 |
| Bourque, J | 1 |
| Garon, J | 1 |
| Chiasson, JL | 1 |
| Masica, DN | 1 |
| Beasley, CM | 2 |
| Noy, S | 1 |
| Pinhas-Hamiel, O | 1 |
| Cowley, G | 1 |
| Springen, K | 1 |
| Finkel, SI | 1 |
| Richter, EM | 1 |
| Clary, CM | 1 |
| Batzar, E | 1 |
| Michelson, D | 1 |
| Amsterdam, JD | 1 |
| Quitkin, FM | 1 |
| Reimherr, FW | 1 |
| Rosenbaum, JF | 1 |
| Zajecka, J | 1 |
| Sundell, KL | 1 |
| Kim, Y | 1 |
| Lin, X | 1 |
| Levitsky, DA | 1 |
| King, JM | 1 |
| Campbell, TC | 1 |
| Robinson, RG | 1 |
| Schultz, SK | 1 |
| Castillo, C | 1 |
| Kopel, T | 1 |
| Kosier, JT | 1 |
| Newman, RM | 1 |
| Curdue, K | 1 |
| Petracca, G | 1 |
| Starkstein, SE | 1 |
| Cash, TF | 1 |
| Brown, MA | 1 |
| Bondi, M | 1 |
| Menozzi, R | 1 |
| Bertolini, M | 1 |
| Venneri, MG | 1 |
| Del Rio, G | 1 |
| Dursun, SM | 1 |
| Devarajan, S | 1 |
| Fujioka, K | 1 |
| Devine, W | 1 |
| Bray, GA | 1 |
| Stinson, JC | 1 |
| Murphy, CM | 1 |
| Andrews, JF | 1 |
| Tomkin, GH | 1 |
| Friedman, H | 1 |
| Brymer, C | 1 |
| Winograd, CH | 1 |
| Yen, TT | 1 |
| Fuller, RW | 1 |
| Wise, SD | 1 |
| Munro, JF | 1 |
| Scott, C | 1 |
| Hodge, J | 1 |
| Darga, LL | 1 |
| Carroll-Michals, L | 1 |
| Botsford, SJ | 1 |
| Lucas, CP | 2 |
| Marcus, MD | 1 |
| Wing, RR | 1 |
| Ewing, L | 1 |
| Kern, E | 1 |
| McDermott, M | 1 |
| Gooding, W | 1 |
| McGuirk, J | 1 |
| Silverstone, T | 1 |
| Cugurra, F | 1 |
| Thompson, WL | 1 |
| Byyny, RL | 1 |
| Dauer, AD | 1 |
| Kirby, RW | 1 |
| Kreindler, TG | 1 |
| Levy, B | 1 |
| McIlwain, HH | 1 |
| Debus, JR | 1 |
| Rush, AJ | 1 |
| Himmel, C | 1 |
| Tyler, D | 1 |
| Polatin, P | 1 |
| Weissenburger, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction[NCT02386475] | Phase 4 | 39 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for fluoxetine and Weight Reduction
| Article | Year |
|---|---|
Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.
Topics: Anti-Obesity Agents; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Fluoxetine; Gly | 2011 |
Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Dru | 2004 |
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetin | 2005 |
Preclinical pharmacology of fluoxetine, a serotonergic drug for weight loss.
Topics: Animals; Appetite Depressants; Eating; Fluoxetine; Serotonin; Weight Loss | 1992 |
Clinical studies with fluoxetine in obesity.
Topics: Adult; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity; Weight Loss | 1992 |
Appraisal of the clinical value of serotoninergic drugs.
Topics: Appetite Depressants; Fenfluramine; Fluoxetine; Humans; Obesity; Serotonin; Weight Loss | 1992 |
33 trials available for fluoxetine and Weight Reduction
| Article | Year |
|---|---|
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
Topics: Adult; Amphetamines; Anti-Obesity Agents; Body Mass Index; Brazil; Cyclobutanes; Diet, Reducing; Die | 2014 |
The slippery slope: prediction of successful weight maintenance in anorexia nervosa.
Topics: Adolescent; Adult; Anorexia Nervosa; Body Image; Body Mass Index; Body Weight; Cognitive Behavioral | 2009 |
Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Bulimia; Cognitive Behavioral Therapy; Double-Blind | 2005 |
Fluoxetine: a randomized clinical trial in the maintenance of weight loss.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Carbohydrates; Cholesterol; Cholesterol, LDL; | 1993 |
An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Drug Therapy, Combination; Female; | 2007 |
Comparison of fluoxetine and placebo in the treatment of obesity.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Fluoxetine; Humans; Obesity; Selective Serot | 1995 |
A study of fluoxetine in obese elderly patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Evaluation S | 1995 |
Fluoxetine increases resting energy expenditure and basal body temperature in humans.
Topics: Adult; Body Temperature; Chemotherapy, Adjuvant; Diet, Reducing; Double-Blind Method; Energy Metabol | 1995 |
Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Diet, Reducing; Double-Blind Method; Female; Flu | 1994 |
Pattern analysis method for assessing successful weight reduction.
Topics: Adult; Aged; Blood Pressure; Confidence Intervals; Counseling; Diabetes Mellitus, Type 2; Double-Bli | 1994 |
Fluoxetine: a randomized clinical trial in the treatment of obesity.
Topics: Adult; Body Mass Index; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity; | 1994 |
The effect of fluoxetine on body weight, body composition and visceral fat accumulation.
Topics: Abdomen; Adipose Tissue; Adult; Body Composition; Double-Blind Method; Fluoxetine; Humans; Magnetic | 1993 |
Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success.
Topics: Double-Blind Method; Fluoxetine; Humans; Obesity; Placebos; Risk Factors; Selective Serotonin Reupta | 1995 |
Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dou | 1996 |
Effect of fluoxetine on food intake of humans living in a residential laboratory.
Topics: Adult; Dietary Carbohydrates; Dietary Fats; Eating; Energy Intake; Female; Fluoxetine; Humans; Male; | 1996 |
The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial.
Topics: Adult; Aged; Body Mass Index; Drug Therapy, Combination; Female; Fenfluramine; Fluoxetine; Humans; L | 1996 |
Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluoxetine | 1997 |
Fluoxetine in medically stable, depressed geriatric patients: effects on weight.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Body Mass Index; Depressive Disor | 1997 |
Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Body Mass Index; Female; | 1999 |
Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Cognition; Depressive Disorder, Major; Double-Blind | 1999 |
Changes in weight during a 1-year trial of fluoxetine.
Topics: Adult; Appetite; Body Mass Index; Body Weight; Depressive Disorder; Female; Fluoxetine; Humans; Male | 1999 |
Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study.
Topics: Activities of Daily Living; Antidepressive Agents, Tricyclic; Cognition Disorders; Depressive Disord | 2000 |
Attitudes about antidepressants: influence of information about weight-related side effects.
Topics: Adolescent; Adult; Antidepressive Agents; Attitude to Health; Body Weight; Drug Information Services | 2000 |
Metabolic effects of fluoxetine in obese menopausal women.
Topics: Antidepressive Agents, Second-Generation; Blood Glucose; Body Temperature Regulation; Double-Blind M | 2000 |
Fluoxetine treatment of the obese diabetic.
Topics: Adult; Blood Glucose; Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blin | 1992 |
An assessment of the thermogenic effects of fluoxetine in obese subjects.
Topics: Adult; Basal Metabolism; Body Temperature Regulation; Double-Blind Method; Female; Fluoxetine; Human | 1992 |
Fluoxetine therapy in obese diabetic and glucose intolerant patients.
Topics: Blood Glucose; Diabetes Mellitus; Double-Blind Method; Female; Fluoxetine; Glucose Tolerance Test; G | 1992 |
Clinical studies with fluoxetine in obesity.
Topics: Adult; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity; Weight Loss | 1992 |
Fluoxetine's effect on weight loss in obese subjects.
Topics: Adolescent; Adult; Double-Blind Method; Fluoxetine; Humans; Middle Aged; Obesity; Time Factors; Weig | 1991 |
A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters.
Topics: Adolescent; Adult; Attitude to Health; Behavior Therapy; Bulimia; Clinical Trials as Topic; Combined | 1990 |
The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects.
Topics: Adolescent; Adult; Appetite; Body Weight; Double-Blind Method; Energy Intake; Fluoxetine; Humans; Ma | 1990 |
Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub).
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Male; Middle | 1989 |
Fluoxetine versus trazodone in the treatment of outpatients with major depression.
Topics: Ambulatory Care; Clinical Trials as Topic; Depressive Disorder; Dizziness; Double-Blind Method; Fluo | 1988 |
22 other studies available for fluoxetine and Weight Reduction
| Article | Year |
|---|---|
Determination of Fluoxetine in Weight Loss Herbal Medicine Using an Electrochemical Sensor Based on rGO-CuNPs.
Topics: Anti-Obesity Agents; Fluoxetine; Graphite; Humans; Plant Extracts; Weight Loss | 2023 |
Dual exposure to stress in different stages of development affects eating behavior of male Wistar rats.
Topics: Age Factors; Animals; Animals, Newborn; Anxiety; Drug Resistance; Eating; Female; Fluoxetine; Food D | 2020 |
An adolescent male with features of EDNOS and obsessive-compulsive disorder.
Topics: Adolescent; Body Mass Index; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; D | 2008 |
A study of electrical conductance of meridian in the obese during weight reduction.
Topics: Adult; Body Mass Index; Case-Control Studies; Diet, Reducing; Electric Impedance; Exercise; Female; | 2004 |
Weight loss dynamics during combined fluoxetine and olanzapine treatment.
Topics: Animals; Benzodiazepines; Fluoxetine; Male; Olanzapine; Rats; Rats, Long-Evans; Selective Serotonin | 2004 |
Daily high doses of fluoxetine for weight loss and improvement in lifestyle before bariatric surgery.
Topics: Adult; Appetite Depressants; Bariatric Surgery; Female; Fluoxetine; Health Behavior; Humans; Life St | 2005 |
Baseline predictors of success when comparing two treatments.
Topics: Anti-Obesity Agents; Fluoxetine; Humans; Obesity; Predictive Value of Tests; Randomized Controlled T | 1994 |
Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
Topics: Adult; Appetite Depressants; Body Mass Index; Drug Therapy, Combination; Fenfluramine; Fluoxetine; H | 2007 |
Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis.
Topics: Animals; Area Under Curve; Behavior, Animal; Bupropion; Catecholamines; Dopamine Uptake Inhibitors; | 2008 |
[Pharmacotherapy for weight loss in patients with type 2 diabetes].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Evidence-Based M | 2007 |
Fluoxetine induced weight loss: a pilot study in postpartum women.
Topics: Adult; Female; Fluoxetine; Humans; Obesity; Pilot Projects; Puerperal Disorders; Weight Loss | 1995 |
Hyperphagia and weight loss during fluoxetine treatment.
Topics: Adult; Depression; Eating; Female; Fluoxetine; Humans; Hyperphagia; Weight Loss | 1994 |
Response to Roback et al.
Topics: Adolescent; Adult; Fluoxetine; Humans; Obesity; Weight Loss | 1995 |
If weight loss persists after other symptoms of depression subside.
Topics: Anorexia; Depressive Disorder; Female; Fluoxetine; Humans; Middle Aged; Weight Loss | 1994 |
Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers.
Topics: Adult; Dietary Carbohydrates; Dietary Proteins; Eating; Female; Fenfluramine; Fluoxetine; Humans; Mo | 1993 |
[The effect of fluoxetine on insulin resistance in non diabetic obese patients].
Topics: Adult; Antidepressive Agents, Second-Generation; Fluoxetine; Glucose Tolerance Test; Humans; Insulin | 1995 |
Effects of serotonergic agents on food-restriction-induced hyperactivity.
Topics: Animals; Antidepressive Agents, Tricyclic; Body Weight; Disease Models, Animal; Eating; Female; Fenc | 1996 |
After fen-phen.
Topics: Antidepressive Agents, Second-Generation; Appetite Depressants; Consumer Product Safety; Fenfluramin | 1997 |
The promotion effect of anorectic drugs on aflatoxin B(1)-induced hepatic preneoplastic foci.
Topics: Adipose Tissue, Brown; Aflatoxin B1; Amphetamine; Animals; Appetite Depressants; Biomarkers; Body Te | 1999 |
Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action?
Topics: Adult; Antidepressive Agents, Second-Generation; Appetite; Depressive Disorder; Drug Therapy, Combin | 2001 |
Fluoxetine in elderly patients: is there cause for concern?
Topics: Age Factors; Aged; Ambulatory Care; Anorexia; Comorbidity; Depressive Disorder; Female; Fluoxetine; | 1992 |
[XXIV. The future of slimming anorectics].
Topics: Fluoxetine; Forecasting; Humans; Weight Loss | 1989 |